Enorama Pharma (ERMA.ST) Stock Analysis & AI Equity Report
Enorama Pharma (ERMA.ST) overview
Enorama Pharma (ERMA.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Enorama Pharma reported revenue of SEK 15.8m and operating profit of SEK -47.5m; the year-end share price was 3.36 SEK and market capitalisation was SEK 178m. Enorama Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Enorama Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-29. Data will be refreshed during report generation.
About Enorama Pharma
Enorama Pharma AB is a Swedish pharmaceutical company focused on developing, manufacturing and commercializing consumer-friendly oral nicotine products. Its portfolio includes nicotine pouches under the NIC-S brand and nicotine chewing gum, sold through own-brand and private-label arrangements. The company also has been exploring a divestment of its nicotine replacement chewing gum business to sharpen focus.
Generate the Enorama Pharma report
Enorama Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Enorama Pharma and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.